• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英格兰成人原发性免疫性血小板减少症的发病率——最新情况

Incidence of adult primary immune thrombocytopenia in England-An update.

作者信息

Doobaree Indraraj Umesh, Conway Katherine, Miah Haroon, Miah Atiqa, Makris Michael, Hill Quentin, Cooper Nicola, Bradbury Charlotte, Newland Adrian, Provan Drew, McDonald Vickie

机构信息

Certara EVA, London, UK.

West Sussex University Hospital, Worthing, West Sussex, UK.

出版信息

Eur J Haematol. 2022 Sep;109(3):238-249. doi: 10.1111/ejh.13803. Epub 2022 Jun 26.

DOI:10.1111/ejh.13803
PMID:35670140
Abstract

BACKGROUND

Adult primary immune thrombocytopenia (ITP) is a rare bleeding disorder of unknown cause. Recent estimates of its incidence and trend over time were acquired for England.

METHOD

The primary ITP population (using ICD 10 code D693 and excluding secondary ITP cases; positive predictive value: 82.6%) was sourced from NHS Digital inpatient and outpatient. Incidence rate (IR) for England and by age groups, sex, and regions were calculated and trends were assessed using average annual percent change (AAPC).

RESULTS

A total of 25 805 patients (mean age 59 years; females 57.8%) diagnosed between 2003 and 2014 was identified. IRs increased from 4.2/100 000 to 6.4/100 000 over this period (AAPC:4.3%). For all sex-specific age groups, the IRs significantly increased over time, except 18-29 years males. The greatest increase was among females aged 30-39 (AAPC:8.7%). In contrast, among ≥70 years, ITP was more common in males (highest IR among ≥80 years males: 23.9/100 000). England's average annual IR was 6.1/100 000 for 2010-14. An estimated 2.5/100 000 (based on UKITP Registry data) was estimated to require 1st line treatment whereas 2.4/100 000 would have 1st and 2nd line treatments within 6 months from diagnosis. IRs for London and East Midlands were the highest (6.5/100 000).

CONCLUSIONS

This study found a rising incidence of primary ITP, with sharp increases among young women and elderly men. These findings put in context the impact of ITP on patients' lives and the healthcare services in England, especially with 17%-50% who may develop chronic ITP and require long-term care.

摘要

背景

成人原发性免疫性血小板减少症(ITP)是一种病因不明的罕见出血性疾病。近期已获取了英格兰地区该病的发病率及随时间变化的趋势。

方法

原发性ITP人群(使用国际疾病分类第十版代码D693且排除继发性ITP病例;阳性预测值:82.6%)来自英国国民医疗服务体系数字化住院和门诊数据。计算了英格兰地区及按年龄组、性别和地区划分的发病率(IR),并使用年均变化百分比(AAPC)评估趋势。

结果

共识别出2003年至2014年间诊断的25805例患者(平均年龄59岁;女性占57.8%)。在此期间,发病率从4.2/10万增至6.4/10万(AAPC:4.3%)。对于所有按性别划分的年龄组,发病率随时间显著增加,但18 - 29岁男性除外。增幅最大的是30 - 39岁女性(AAPC:8.7%)。相比之下,在70岁及以上人群中ITP在男性中更为常见(80岁及以上男性发病率最高:23.9/10万)。2010 - 2014年英格兰的年均发病率为6.1/10万。据估计,每10万人中有2.5人(基于英国ITP登记数据)需要一线治疗,而每10万人中有2.4人在确诊后6个月内需要一线及二线治疗。伦敦和东米德兰兹地区的发病率最高(6.5/10万)。

结论

本研究发现原发性ITP的发病率呈上升趋势,年轻女性和老年男性增幅明显。这些发现说明了ITP对英格兰患者生活及医疗服务产生的影响,尤其是17% - 50%可能发展为慢性ITP并需要长期护理的患者。

相似文献

1
Incidence of adult primary immune thrombocytopenia in England-An update.英格兰成人原发性免疫性血小板减少症的发病率——最新情况
Eur J Haematol. 2022 Sep;109(3):238-249. doi: 10.1111/ejh.13803. Epub 2022 Jun 26.
2
Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis.美国临床实践中的原发性免疫性血小板减少症:诊断后 12 个月内的发病率和医疗保健负担。
J Med Econ. 2020 Feb;23(2):184-192. doi: 10.1080/13696998.2019.1669329. Epub 2019 Oct 9.
3
Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort.新诊断的成人免疫性血小板减少症:临床流行病学、治疗暴露和演变。CARMEN 多中心前瞻性队列研究结果。
Am J Hematol. 2017 Jun;92(6):493-500. doi: 10.1002/ajh.24702. Epub 2017 Mar 20.
4
Characteristics and management of primary and other immune thrombocytopenias: Spanish registry study.原发性及其他免疫性血小板减少症的特征与管理:西班牙注册研究
Hematology. 2017 Sep;22(8):484-492. doi: 10.1080/10245332.2017.1311442. Epub 2017 Apr 17.
5
Misdiagnosed thrombocytopenia in children and adolescents: analysis of the Pediatric and Adult Registry on Chronic ITP.儿童和青少年血小板减少症的误诊:慢性 ITP 儿科和成人登记处的分析。
Blood Adv. 2021 Mar 23;5(6):1617-1626. doi: 10.1182/bloodadvances.2020003004.
6
Secondary immune thrombocytopenia in children: Characteristics and outcome of a large cohort from two Spanish centres.儿童继发性免疫性血小板减少症:来自两个西班牙中心的大型队列的特征和结局。
Acta Paediatr. 2021 Jun;110(6):1952-1958. doi: 10.1111/apa.15765. Epub 2021 Mar 16.
7
Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry.在常规临床实践中用罗米司亭治疗原发免疫性血小板减少症(ITP):来自英国 ITP 注册研究的回顾性研究。
Eur J Haematol. 2019 May;102(5):416-423. doi: 10.1111/ejh.13221. Epub 2019 Mar 7.
8
Analysis of the impact and burden of illness of adult chronic ITP in the US.美国成人慢性 ITP 的疾病影响和负担分析。
Curr Med Res Opin. 2009 Dec;25(12):2961-9. doi: 10.1185/03007990903362388.
9
Chronic refractory immune thrombocytopenia in adolescents and young adults.青少年和年轻成人的慢性难治性免疫性血小板减少症。
Br J Haematol. 2023 Oct;203(1):36-42. doi: 10.1111/bjh.19081.
10
Geographic disparities in the care and outcomes in adult chronic immune thrombocytopenia.成人慢性免疫性血小板减少症治疗及预后的地域差异
Thromb Res. 2023 May;225:87-94. doi: 10.1016/j.thromres.2023.03.011. Epub 2023 Mar 30.

引用本文的文献

1
Appropriate Management of Thrombotic Risk in Patients With Primary Immune Thrombocytopenia in the UK: A Modified Delphi Consensus.英国原发性免疫性血小板减少症患者血栓形成风险的恰当管理:一项改良德尔菲共识
EJHaem. 2025 Sep 3;6(5):e70134. doi: 10.1002/jha2.70134. eCollection 2025 Oct.
2
Multicenter Single-Blind Randomized Controlled Trial of the Romiplostim Biosimilar.罗米司亭生物类似药的多中心单盲随机对照试验
EJHaem. 2025 Jul 24;6(4):e70105. doi: 10.1002/jha2.70105. eCollection 2025 Aug.
3
Risk Factors Associated With Thrombocytopenia Induced by Intravenous Immunoglobulin Formulations: An Analysis Using the JADER database.
静脉注射免疫球蛋白制剂所致血小板减少症的相关危险因素:使用日本药品不良反应报告数据库(JADER)的分析
In Vivo. 2025 Jul-Aug;39(4):2320-2327. doi: 10.21873/invivo.14028.
4
Avatrombopag for the Treatment of Immune Thrombocytopenia.阿伐曲泊帕用于治疗免疫性血小板减少症。
Eur J Haematol. 2025 May;114(5):733-746. doi: 10.1111/ejh.14395. Epub 2025 Feb 4.
5
Can Machine Learning Assist in Diagnosis of Primary Immune Thrombocytopenia? A Feasibility Study.机器学习能辅助诊断原发性免疫性血小板减少症吗?一项可行性研究。
Diagnostics (Basel). 2024 Jun 26;14(13):1352. doi: 10.3390/diagnostics14131352.
6
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) gene polymorphisms in a cohort of Egyptian patients with immune thrombocytopenia (ITP).一组埃及免疫性血小板减少症(ITP)患者的细胞毒性T淋巴细胞相关抗原4(CTLA-4)基因多态性
Blood Res. 2024 Mar 1;59(1):8. doi: 10.1007/s44313-024-00011-z.
7
Therapeutic Outcomes of High Dose-Dexamethasone versus Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim Strategies in Persistent, Chronic, Refractory, and Relapsed Immune Thrombocytopenia Patients.高剂量地塞米松与泼尼松龙+硫唑嘌呤、利妥昔单抗、艾曲泊帕和罗米司亭治疗持续性、慢性、难治性和复发性免疫性血小板减少症患者的疗效比较
Pharmaceuticals (Basel). 2023 Aug 29;16(9):1215. doi: 10.3390/ph16091215.
8
Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.成人免疫性血小板减少症中血小板生成素受体激动剂的应用:系统评价和中欧专家共识。
Ann Hematol. 2023 Apr;102(4):715-727. doi: 10.1007/s00277-023-05114-8. Epub 2023 Feb 24.
9
Older Adults and Immune Thrombocytopenia: Considerations for the Clinician.老年人与免疫性血小板减少症:临床医生的相关考虑。
Clin Interv Aging. 2023 Jan 26;18:115-130. doi: 10.2147/CIA.S369574. eCollection 2023.